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2360hypothesis of inferiority (that one hopes to reject to
establish noninferiority). In the case of the SECU-
RITY trial, if all patients in the 6-month arm had
stopped treatment at the planned time, more com-
posite events may have occurred and the difference
with the 12-month treatment arm may have been
greater.
In any case, it is unfortunate that the conclusions
of this trial should contradict the results because of
what appears to be an arithmetic error.*Thomas Perneger, MD, PhD
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Geneva University Hospitals
6 rue Gabrielle-Perret-Gentil
Geneva, Geneva 1211
Switzerland
E-mail: Thomas.Perneger@hcuge.ch
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SECURITY Did Not Establish NoninferiorityWe thank Dr. Kaneda and Dr. Perneger for their
interest in our paper (1), giving us the possibility to
clarify some relevant aspects of the statistical anal-
ysis of our SECURITY (Second-Generation Drug-
Eluting Stent Implantation Followed by 6- Versus
12-Month Dual Antiplatelet Therapy) randomized
noninferiority trial.
We submitted both letters to Professor Bruno
Mario Cesana, the statistician of the SECURITY trial,
and his answer is the following:
Because the conﬁdence interval (CI) calculation
proposed methods (2,3) for the difference be-
tween 2 proportions give different results
possibly leading to different conclusions in the
analysis of noninferiority studies in which the
CI approach is used, we calculated, according
to Thomas and Gart (4), the CI limits of the
odds ratio (OR) that can be “translated” into
the upper and the lower CI limits for the dif-
ference between 2 proportions. We used the
approximate OR 90% CI, due to the much
higher coverage of the “exact” OR CI.As a result, the data in Table 5 give an OR of
1.21 with 90% CI: 0.78 to 1.89, translated as
-0.0093 to 0.024. Consequently, “6 to 12
months” should be considered “6 months” and
“95% CI” as “90% CI” only for the primary
efﬁcacy composite endpoint. In addition, the
90% CI are 0.49% to 1.29% for the comparison
at 6 months and -0.93% to 2.4% for the com-
parison at 12 months.
The unilateral 95% upper limit of 2.4%,
greater than 2%, does not allow us to conclude
for the noninferiority. However, from the re-
sults of the landmark analysis (not shown in
the paper because of space limitations) after
having excluded the events that occurred in
the ﬁrst 6 months in which the treatment is
equal for the 2 arms and in which, by chance,
more events occurred in the 6-month dual
antiplatelet therapy (DAPT) arm, there are
23 events on 674 patients (0.0341; 95%
CI: 0.0234 to 0.0480) in the 6-month DAPT
arm against 22 events on 712 patients (0.0341;
95% CI: 0.0210 to 0.0438) in the 12-month
DAPT arm.
The SECURITY trial (1) has been stopped
without enrolling the planned sample size of
1,370 patients in each treatment group; so, if
the proportions are considered on the expected
sample size, the 95% unilateral upper limit of
their difference is 0.020 and 0.019 from Agresti
and Caffo’s (3) method.
As we have been cautious in the SECURITY paper
(1) to state the conclusiveness of noninferiority, the
same applies to the lack of noninferiority. The bot-
tom line is that with insufﬁcient power, the con-
clusions remain uncertain. Nevertheless, the data
obtained from the SECURITY study are a contribu-
tion to test the hypothesis that shorter duration of
DAPT following implantation of second-generation
drug-eluting stents is as safe and effective as 12
months of therapy. This study underscores that
larger patient enrollment is necessary to answer this
question.*Antonio Colombo, MD
Alaide Chieffo, MD
on behalf of the SECURITY Investigators
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San Raffaele Scientiﬁc Institute
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